Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

August 27, 2014 Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T cell and cancer vaccine product candidates in a variety of blood …